BACKGROUND: An increased or normal serum TSH concentration, despite elevated thyroid hormone levels, is observed in resistance to thyroid hormone (RTH) and TSH-secreting adenomas (TSHomas). When coexistent with a differentiated thyroid cancer (DTC), maintenance of a suppression of TSH is challenging. OBJECTIVES: The aim of the study was to discuss the pitfalls arising from the failure to suppress TSH secretion in DTC and the strategies for proper treatment of DTC in association with RTH and TSHoma. METHODS: Four unusual cases of DTC associated with TSHoma (2 cases), RTH (1 case), and an elevated TSH of unknown etiology (1 case) are presented, and the literature is reviewed. RESULTS: Although a persistent mild TSH elevation may not be a risk factor for the development of DTC, it represents an important problem during the treatment of DTC. Aggressive treatment options should be applied in the proper order to prevent tumor recurrence and persistence in the absence of ideal TSH suppression. CONCLUSIONS: Although there is no agreed consensus regarding the management of DTC in the presence of persistent hyperthyrotropinemia, complete tumor removal followed by radioablation and attempts to reduce the serum TSH to the lowest tolerable level are recommended. The outcomes in the reported cases have not been unfavorable, despite the persistence of nonsuppressed TSH.
BACKGROUND: An increased or normal serum TSH concentration, despite elevated thyroid hormone levels, is observed in resistance to thyroid hormone (RTH) and TSH-secreting adenomas (TSHomas). When coexistent with a differentiated thyroid cancer (DTC), maintenance of a suppression of TSH is challenging. OBJECTIVES: The aim of the study was to discuss the pitfalls arising from the failure to suppress TSH secretion in DTC and the strategies for proper treatment of DTC in association with RTH and TSHoma. METHODS: Four unusual cases of DTC associated with TSHoma (2 cases), RTH (1 case), and an elevated TSH of unknown etiology (1 case) are presented, and the literature is reviewed. RESULTS: Although a persistent mild TSH elevation may not be a risk factor for the development of DTC, it represents an important problem during the treatment of DTC. Aggressive treatment options should be applied in the proper order to prevent tumor recurrence and persistence in the absence of ideal TSH suppression. CONCLUSIONS: Although there is no agreed consensus regarding the management of DTC in the presence of persistent hyperthyrotropinemia, complete tumor removal followed by radioablation and attempts to reduce the serum TSH to the lowest tolerable level are recommended. The outcomes in the reported cases have not been unfavorable, despite the persistence of nonsuppressed TSH.
Authors: Donald S A McLeod; Karen F Watters; Anthony D Carpenter; Paul W Ladenson; David S Cooper; Eric L Ding Journal: J Clin Endocrinol Metab Date: 2012-05-23 Impact factor: 5.958
Authors: Alfonso Massimiliano Ferrara; Kazumichi Onigata; Oya Ercan; Helen Woodhead; Roy E Weiss; Samuel Refetoff Journal: J Clin Endocrinol Metab Date: 2012-02-08 Impact factor: 5.958
Authors: David S Cooper; Gerard M Doherty; Bryan R Haugen; Bryan R Hauger; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Furio Pacini; Martin Schlumberger; Steven I Sherman; David L Steward; R Michael Tuttle Journal: Thyroid Date: 2009-11 Impact factor: 6.568
Authors: Rosa Maria Paragliola; Rosa Maria Lovicu; Pietro Locantore; Paola Senes; Paola Concolino; Ettore Capoluongo; Alfredo Pontecorvi; Salvatore Maria Corsello Journal: Thyroid Date: 2011-06-07 Impact factor: 6.568
Authors: Hee Kyung Kim; Doi Kim; Eun Hyung Yoo; Ji In Lee; Hye Won Jang; Alice Hyun Kyung Tan; Kyu Yeon Hur; Jae Hyeon Kim; Kwang-Won Kim; Jae Hoon Chung; Sun Wook Kim Journal: J Korean Med Sci Date: 2010-08-12 Impact factor: 2.153
Authors: João Vinagre; Fátima Borges; António Costa; Maria Inês Alvelos; Glaúcia Mazeto; Manuel Sobrinho-Simões; Paula Soares Journal: Front Mol Biosci Date: 2014-09-02